| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e75810cb7d022e16fc3e012a68ae090 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C49-215
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C59-68 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C59-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C49-215
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-343 |
| filingDate |
2016-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbb1de50ae680c6ac07d43be2c1f23e7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_791d38ba6809fd4820a25043c76e6b97
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e71aab16bc7bbfe6833712128227f6f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0eb5d8c07a215e276c88369101abb1de
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1182ab8c3cd55612d13f0ccc47ff22e6 |
| publicationDate |
2018-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2018369190-A1 |
| titleOfInvention |
Compounds for targeting thyroid hormone receptor alpha isoforms and methods of use thereof |
| abstract |
Two isoforms of thyroid receptor alpha (THRα1 and THRα2) have been found to be associated with the growth of cancer. Use of inhibitors of THRα1 (Formula I) and/or agonists of THRα2 (Formula II) in the treatment of such cancers is disclosed. Treatment of other disorders associated with such receptors is also contemplated, as is the use of diagnostic methods for predicting therapeutic outcomes based on the levels of expression of THRα1 and THRaα2 in a tissue sample. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023123695-A1 |
| priorityDate |
2015-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |